At the 22nd ICOCS annual meeting held today, Ning Yihua said that brain-computer interface dual-target DBS is the last resort for intractable mental diseases, and that Chinese companies and clinicians have achieved a landmark breakthrough in the treatment of intractable mental diseases. A global “first” has been achieved — DBS, a dual-target brain-computer interface targeting opioid addiction, has been approved for sale in China. Jingyu Medical initiated two brain-computer interface dual-target DBS clinical trials in 2016 and 2021 to treat refractory obsessive-compulsive disorder. The full response rate for 6 months was over 75%. Note: Jingyu Healthcare is an enterprise in the field of brain-computer interface for the treatment of addiction and psychiatric disorders. In December 2025, the company Neurestora® was approved for listing by the China Drug Administration for relapse prevention and adjuvant treatment for refractory moderate to severe opioid addiction patients, becoming the world's first brain-computer interface dual-target DBS system approved to treat drug addiction.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.